Literature DB >> 20002297

Comparative serum proteomic analysis of patients with acute-on-chronic liver failure: alpha-1-acid glycoprotein maybe a candidate marker for prognosis of hepatitis B virus infection.

F Ren1, Y Chen, Y Wang, Y Yan, J Zhao, M Ding, J Zhang, Y Jiang, Y Zhai, Z Duan.   

Abstract

The acute-on-chronic liver failure (AoCLF) caused by hepatitis B virus (HBV) infection remains to be a challenge in clinics with a high mortality rate in China, and it is important to identify biomarkers to foresee the prognosis of patients with HBV. The current study analysed serum proteome changes of acute-on-chronic liver failure as a result of acute exacerbation of chronic hepatitis B infection. Serum samples were collected from normal subjects (NS, n = 8), patients with chronic hepatitis B (CHB, n = 12) and patients with AoCLF (n = 12). After removal of albumin/IgG and ultramembrane centrifugation, serum proteins were separated by two-dimensional gel electrophoresis. Differentially expressed spots were identified by matrix-associated laser desorption ionization time-of-flight tandem mass spectrometry. Through the removal of albumin/IgG and ultramembrane centrifugation, the well-resolved and reproducible two-dimensional gel electrophoresis (2-DE) profiles were obtained. A total of 23 proteins were identified on 2-DE profiles by their differential expression between the three cohorts. Mass spectrometry analysis resulted in the identification of 12 proteins unambiguously. Western blot analysis confirmed the proteomics results that the α1-acid glycoprotein (α1-AGP) levels decrease significantly in plasma of patients with AoCLF, but somewhat decreased in patients with chronic HBV. Further α1-AGP levels in bulk serum samples were measured by immune turbidimetry including normal subjects group (n = 25), acute hepatitis group (n = 36), chronic hepatitis group (n = 52) and AoCLF group (n = 48), the level of α1-AGP in AoCLF groups sharply decrease than other groups. Our study shows that α1-AGP may be a potential plasma biomarker for AoCLF diagnosis because of acute exacerbation of chronic hepatitis B infection.
© 2009 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20002297     DOI: 10.1111/j.1365-2893.2009.01242.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  15 in total

Review 1.  Approaches for targeted proteomics and its potential applications in neuroscience.

Authors:  Sumit Sethi; Dipti Chourasia; Ishwar S Parhar
Journal:  J Biosci       Date:  2015-09       Impact factor: 1.826

2.  Plasma gelsolin protein: a candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach.

Authors:  Cristina Marrocco; Sara Rinalducci; Ashraf Mohamadkhani; Gian Maria D'Amici; Lello Zolla
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

Review 3.  Orosomucoid, an acute response protein with multiple modulating activities.

Authors:  Zhumin Luo; Hong Lei; Yang Sun; Xia Liu; Ding-Feng Su
Journal:  J Physiol Biochem       Date:  2015-02-25       Impact factor: 4.158

4.  Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.

Authors:  Daxian Wu; Sainan Zhang; Zhongyang Xie; Ermei Chen; Qunfang Rao; Xiaoli Liu; Kaizhou Huang; Jing Yang; Lanlan Xiao; Feiyang Ji; Zhengyi Jiang; Yalei Zhao; Xiaoxi Ouyang; Danhua Zhu; Xiahong Dai; Zhouhua Hou; Bingjie Liu; Binbin Deng; Ning Zhou; Hainv Gao; Zeyu Sun; Lanjuan Li
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

5.  Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers.

Authors:  Hirofumi Uto; Shuji Kanmura; Yoichiro Takami; Hirohito Tsubouchi
Journal:  Proteome Sci       Date:  2010-12-31       Impact factor: 2.480

6.  Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder.

Authors:  Y R Song; B Wu; Y T Yang; J Chen; L J Zhang; Z W Zhang; H Y Shi; C L Huang; J X Pan; P Xie
Journal:  Braz J Med Biol Res       Date:  2015-09-08       Impact factor: 2.590

7.  Two classifiers based on serum peptide pattern for prediction of HBV-induced liver cirrhosis using MALDI-TOF MS.

Authors:  Yuan Cao; Kun He; Ming Cheng; Hai-Yan Si; He-Lin Zhang; Wei Song; Ai-Ling Li; Cheng-Jin Hu; Na Wang
Journal:  Biomed Res Int       Date:  2013-02-19       Impact factor: 3.411

8.  iTRAQ-based proteomic analysis of hepatic tissues from patients with hepatitis B virus-induced acute-on-chronic liver failure.

Authors:  Liang Peng; Jing Liu; Yang-Mei Li; Zhan-Lian Huang; Pei-Pei Wang; Yu-Bao Zheng; Yun-Peng Hua; Zhi-Liang Gao
Journal:  Exp Ther Med       Date:  2015-09-04       Impact factor: 2.447

9.  Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study.

Authors:  Jamal Sarvari; Zahra Mojtahedi; Seyed Ali Reza Taghavi; Yasuhiro Kuramitsu; Mahmoud Shamsi Shahrabadi; Abbas Ghaderi; Kazuyuki Nakamura
Journal:  Hepat Mon       Date:  2013-07-03       Impact factor: 0.660

10.  Serum proteomics analysis and comparisons using iTRAQ in the progression of hepatitis B.

Authors:  Liang Peng; Jing Liu; Yang-Mei Li; Zhan-Lian Huang; Pei-Pei Wang; Yu-Rong Gu; Yu-Bao Zheng; Zhi-Liang Gao
Journal:  Exp Ther Med       Date:  2013-09-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.